Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peter S. Galatin
Observed name:
P. Galatin
Institutions:
Stanford Medicine,
Stanford University
Observed institutions:
Virginia Commonwealth University,
Stanford Medicine,
Stanford University
OpenAlex ID:
A5000512574
A Nonpeptidic Sulfonamide Inhibits the p53−mdm2 Interaction and Activates p53-Dependent Transcription in mdm2-Overexpressing Cells
2004
·
Peter S. Galatin
, Donald J. Abraham
·
Journal of Medicinal Chemistry
·
105
QSAR: Hydropathic analysis of inhibitors of the p53–mdm2 interaction
2001
·
Peter S. Galatin
, Donald J. Abraham
·
Proteins Structure Function and Bioinformatics
·
20
A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors
2008
·
L. S. Rosen
, P. Galatin
, et al.
·
Journal of Clinical Oncology
·
17
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
2010
·
Peter S. Galatin
, Ranjana H. Advani
, et al.
·
Investigational New Drugs
·
13
Show more works
View as search
Works count:
5
Citation count:
156
H-index:
4
I10-index:
4
Year
Topic
Type